The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma

Table 1

Demography.

Characteristic	1st TKIs/2nd chemotherapy	1st chemotherapy/2nd TKIs	value
	()	()
Age, yr, median (IQR)	59 (52–69)	58 (52–64)	0.15
Female, (%)	30 (54.5%)	27 (48.2%)	0.5
Smoking, (%)	25 (45.5%)	17 (30.4%)	0.1
Performance status at beginning of 1st-line treatment
0-1	42 (76.4%)	47 (83.9%)	0.32
2	9 (16.4%)	8 (14.3%)	0.76
>2	4 (7.3%)	1 (1.8%)	0.16
EGFR mutation status
19Del	21 (38.1%)	23 (41.0%)	0.74
L858R	32 (58.2%)	31 (55.4%)
Others	2 (3.7%)	2 (3.6%)
Progression site from each 1st-line treatment
Primary lung	17 (30.9%)	19 (33.9%)	0.73
Lung to lung metastasis	10 (18.2%)	9 (16.1%)	0.77
Bone	6 (10.9%)	9 (16.1%)	0.43
Pleural effusion	6 (10.9%)	7 (12.4%)	0.79
CNS	9 (16.4%)	5 (8.9%)	0.52
Liver	3 (5.5%)	2 (3.6%)	0.63
Adrenal gland	2 (3.6%)	3 (5.4%)	0.66
Others	2 (3.6%)	2 (3.6%)	0.99
Performance status at beginning of 2nd line treatment
0-1	29 (52.7%)	38 (67.9%)	0.10
2	21 (38.2%)	15 (26.8%)	0.20
>2	5 (9.1%)	3 (5.3%)	0.45

IQR: interquartile range; CNS: central nervous system.